<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390036</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 17-02</org_study_id>
    <nct_id>NCT03390036</nct_id>
  </id_info>
  <brief_title>Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up</brief_title>
  <acronym>Cingal17-02</acronym>
  <official_title>Extension Study to Cingal 16-02: Trial Extension to 39 Week Follow Up in the Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this sub-study is to evaluate the efficacy and safety at 39 week follow up
      of a single injection of Cingal for relief of joint pain in subjects with OA of the knee who
      have not responded to conservative treatment (weight reduction, physical therapy, pain
      medications, etc.).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OMERACT-OARSI Responder Rate</measure>
    <time_frame>39 weeks</time_frame>
    <description>Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">576</enrollment>
  <condition>Osteo Arthritis Knee</condition>
  <arm_group>
    <arm_group_label>Cingal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monovisc</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone Hexacetonide (TH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A 1 mL unit dose of Triamcinolone Hexacetonide (TH) supplied as 20 mg/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)</description>
    <arm_group_label>Cingal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monovisc</intervention_name>
    <description>A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose</description>
    <arm_group_label>Monovisc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide</intervention_name>
    <description>20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide</description>
    <arm_group_label>Triamcinolone Hexacetonide (TH)</arm_group_label>
    <other_name>TH</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects meet the inclusion criteria for Cingal 16-02 and signed the informed consent.

          2. Subject is able to understand and comply with the requirements of Cingal 17-02 and
             voluntarily provides consent.

        Exclusion Criteria:

        Patients will not be rescreened at enrollment to Cingal 17-02 as these patients met the
        inclusion / exclusion criteria for the Cingal 16-02 clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Hangody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uzsoki Hospital, Department of Traumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Health Center of Downtown-Lipotvaros, Orthopedic Outpatient Clinic (Belvárosi-Lipótvárosi Egészségügyi Szolgálat Ortopeadia)</name>
      <address>
        <city>Budapest</city>
        <zip>1051</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

